Minnesota law enforcement intensifies patrols for impaired drivers during holidays, inspired by a family tragedy and ...
Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared ...
18hon MSN
Non-invasive closed-loop spinal stimulation enables paraplegic patients to regain stepping control
Spinal cord injury (SCI) rostral to the lumbar locomotor center disrupts communication between the brain and the spinal ...
When the hospital germ Pseudomonas aeruginosa infects the body, it uses the sugar-binding protein LecA to attach itself to ...
The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...
A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.
Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...
In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback